Results 151 to 160 of about 2,265 (188)

Chronic rhinosinusitis with and without nasal polyps: the state-of-the-art of current treatment strategies and future developments. [PDF]

Front Allergy
Nappi E, Marzio V, Giombi F, Costanzo G, Merli S, Nicolosi S, Cavaglià E, Rizzini FL, Traversi S, Vrenna A, Vassallo S, Pace GM, Lombardi C, Rossi CM, Puggioni F, Malvezzi L, Canonica GW, Paoletti G, Heffler E.   +18 more
europepmc   +1 more source

Epithelial-derived cytokines in the pathogenesis of severe asthma. [PDF]

Front Allergy
Pham DD, Kim TB.
europepmc   +1 more source

Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review. [PDF]

J Pers Med
Lavere PF, Phillips KM, Hanania NA, Adrish M.   +3 more
europepmc   +1 more source

Real-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry. [PDF]

J Clin Med
Papaioannou O, Christopoulos I, Tsiri P, Sampsonas F, Karkoulias K, Lykouras D, Sotiropoulou V, Theohari E, Papalexatos D, Komninos D, Christopoulos A, Tzouvelekis A.   +11 more
europepmc   +1 more source

Biologic Therapies for Severe Asthma: Current Insights and Future Directions. [PDF]

J Clin Med
Faria N, Costa MI, Fernandes AL, Fernandes A, Fernandes B, Machado DC, Machado F, Simão L, Ribeiro L, Ferreira L, Boaventura R, Lima R, Ferreira J.   +12 more
europepmc   +1 more source

Tezepelumab in Patients With Severe Asthma: Response at 3 Months

Journal of Investigational Allergy and Clinical Immunology
J C, Miralles-López, R, Andújar-Espinosa, F J, Bravo-Gutierrez, S, Cabrejos-Perotti, M, Ramírez-Hernández, C, Díaz-Chantar, M J, Pajarón-Fernández, J, Valverde-Molina, V, Pérez-Fernández   +8 more
openaire   +2 more sources

Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma. [PDF]

Adv Ther
Panettieri RA, Kraft M, Castro M, Bober M, Lindsley AW, Shelkrot M, Ambrose CS.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tezepelumab for asthma

Drugs of Today, 2022
The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can promote and regulate inflammatory processes through the production of cytokines, namely interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), known as "alarmins".
Nolasco, Santi, Pelaia, Corrado, Scioscia, Giulia, Campisi, Raffaele, Crimi, Claudia   +4 more
openaire   +2 more sources

Tezepelumab: First Approval

Drugs, 2022
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the pathogenesis of asthma. Tezepelumab (tezepelumab-ekko; TEZSPIRE™) is a first-in-class human IgG2λ monoclonal antibody that inhibits the action of TSLP. Administered subcutaneously, it is being developed by Amgen and AstraZeneca for the treatment of asthma ...
openaire   +2 more sources

Tezepelumab (Tezspire)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +1 more source